CELZ (Creative Medical Technology Holdings) Cyclically Adjusted PB Ratio: (As of Jul. 25, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CELZ Creative Medical Technology Holdings Inc CELZ
34 GF Score
Price $0.81
GF Value $0.32
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Creative Medical Technology Holdings Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Creative Medical Technology Holdings  (NAS:CELZ) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Creative Medical Technology Holdings Cyclically Adjusted PB Ratio Related Terms


Creative Medical Technology Holdings Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Creative Medical Technology Holdings's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Creative Medical Technology Holdings Cyclically Adjusted PB Ratio Chart

Creative Medical Technology Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Creative Medical Technology Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CELZ vs FBLG, GLMD, ALZN: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Creative Medical Technology Holdings's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Creative Medical Technology Holdings Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Creative Medical Technology Holdings's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Creative Medical Technology Holdings's Cyclically Adjusted PB Ratio falls into.


CELZ
34GF Score
Creative Medical Technology Holdings Inc CELZ
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Creative Medical Technology Holdings Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Creative Medical Technology Holdings's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Creative Medical Technology Holdings's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book=Book Value per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.653/330.2130*330.2130
=1.653

Current CPI (Mar. 2026) = 330.2130.

Creative Medical Technology Holdings Quarterly Data

Book Value per Share CPI Adj_Book
201606 0.000 241.018 0.000
201609 0.000 241.428 0.000
201612 0.000 241.432 0.000
201703 0.000 243.801 0.000
201706 0.000 244.955 0.000
201709 0.000 246.819 0.000
201712 0.000 246.524 0.000
201803 -7,934.000 249.554 -10,498.369
201806 -10,595.000 251.989 -13,883.966
201809 -7,357.000 252.439 -9,623.620
201812 -3,998.000 251.233 -5,254.849
201903 -3,608.000 254.202 -4,686.857
201906 -1,320.000 256.143 -1,701.710
201909 -1,188.667 256.759 -1,528.723
201912 -2,018.500 256.974 -2,593.784
202003 -187.353 258.115 -239.685
202006 -85.878 257.797 -110.001
202009 -29.253 260.280 -37.113
202012 -258.481 260.474 -327.686
202103 -12.781 264.877 -15.934
202106 -4.832 271.696 -5.873
202109 -1.488 274.310 -1.791
202112 16.117 278.802 19.089
202203 14.347 287.504 16.478
202206 16.507 296.311 18.396
202209 15.675 296.808 17.439
202212 11.268 296.797 12.537
202303 10.527 301.836 11.517
202306 9.594 305.109 10.383
202309 8.693 307.789 9.326
202312 7.528 306.746 8.104
202403 6.811 312.332 7.201
202406 5.690 314.175 5.980
202409 4.930 315.301 5.163
202412 3.628 315.605 3.796
202503 3.123 319.799 3.225
202506 2.645 322.561 2.708
202509 2.167 324.800 2.203
202512 2.033 324.054 2.072
202603 1.653 330.213 1.653

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Creative Medical Technology Holdings (CELZ) Overvalued in 2026?

Based on GuruFocus' analysis, Creative Medical Technology Holdings stock appears to be overvalued. The current stock price of $0.81 is trading 153.2% above its estimated GF Value™ of $0.32. GuruFocus considers Creative Medical Technology Holdings to be Significantly Overvalued.

Key valuation signals for CELZ:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: $0.32 vs. price of $0.81 (153.2% above fair value)
  • GF Score™: 34/100 with 4 warning signs

No single metric tells the full story. See the CELZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Creative Medical Technology Holdings Business Description

Address 211 E Osborn Road, Phoenix, AZ, USA, 85012
Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.
34GF Score

Get the complete analysis for CELZ

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.81
Price
$0.32
GF Value